Literature DB >> 19596456

Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy.

Lester M Davids1, Britta Kleemann, Susan Cooper, Susan H Kidson.   

Abstract

Photodynamic therapy (PDT) as a regime for melanoma is of limited success due to factors such as the efficacy of the photosensitizer used, penetration depth and the presence of pigment. We characterised a pigmented and an unpigmented melanoma cell line with respect to their phenotypes. Cell viability was assessed after exposure to hypericin, a UVA-activated photosensitizer. Exposure to 3 microM activated hypericin induced a cytoprotective (autophagic) response from both cell lines. However, the pigmented cells accumulated a large amount of glycogen in their cytoplasm. We hypothesise that the treatment induces an initial cytoprotective response through autophagy, but with increased stress results in a different mode of cell death in pigmented melanoma cells from unpigmented cells. These results indicate that hypericin-PDT could be an adjuvant therapy for melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596456     DOI: 10.1016/j.cellbi.2009.06.026

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  14 in total

Review 1.  Mechanisms of resistance to photodynamic therapy.

Authors:  A Casas; G Di Venosa; T Hasan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  The effectiveness and safety of X-PDT for cutaneous squamous cell carcinoma and melanoma.

Authors:  Lei Shi; Pei Liu; Jing Wu; Lun Ma; Han Zheng; Michael P Antosh; Haiyan Zhang; Bo Wang; Wei Chen; Xiuli Wang
Journal:  Nanomedicine (Lond)       Date:  2019-06-05       Impact factor: 5.307

Review 3.  Photodynamic therapy for cancer: Role of natural products.

Authors:  Behzad Mansoori; Ali Mohammadi; Mohammad Amin Doustvandi; Fatemeh Mohammadnejad; Farzin Kamari; Morten F Gjerstorff; Behzad Baradaran; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2019-05-04       Impact factor: 3.631

Review 4.  Hypericins as potential leads for new therapeutics.

Authors:  Anastasia Karioti; Anna Rita Bilia
Journal:  Int J Mol Sci       Date:  2010-02-04       Impact factor: 5.923

Review 5.  Melanoma resistance to photodynamic therapy: new insights.

Authors:  Ying-Ying Huang; Daniela Vecchio; Pinar Avci; Rui Yin; Maria Garcia-Diaz; Michael R Hamblin
Journal:  Biol Chem       Date:  2013-02       Impact factor: 3.915

6.  Laser light activation of a second-generation photosensitiser and its use as a potential photomodulatory agent in skin rejuvenation.

Authors:  V Van Kets; A Karsten; L M Davids
Journal:  Lasers Med Sci       Date:  2012-05-12       Impact factor: 3.161

7.  The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC.

Authors:  Eliza Guti; Zsolt Regdon; Isotta Sturniolo; Alexandra Kiss; Katalin Kovács; Máté Demény; Árpád Szöőr; György Vereb; János Szöllősi; Csaba Hegedűs; Zsuzsanna Polgár; László Virág
Journal:  Cancer Immunol Immunother       Date:  2022-01-23       Impact factor: 6.630

8.  Silibinin Induced Human Glioblastoma Cell Apoptosis Concomitant with Autophagy through Simultaneous Inhibition of mTOR and YAP.

Authors:  Zhuan-Li Bai; Vincent Tay; Shu-Zhong Guo; Juan Ren; Mao-Guo Shu
Journal:  Biomed Res Int       Date:  2018-03-26       Impact factor: 3.411

Review 9.  Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma.

Authors:  Xin-Ying Li; Liu-Chang Tan; Li-Wen Dong; Wan-Qi Zhang; Xiao-Xiao Shen; Xiao Lu; Hong Zheng; Yuan-Gang Lu
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

10.  St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death.

Authors:  Britta Kleemann; Benjamin Loos; Thomas J Scriba; Dirk Lang; Lester M Davids
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.